Furthermore, CD96 shows strong concordance with other immune checkpoint proteins such as TIGIT, CD226, and CRTAM, as well as established markers including PD-L1, CTLA-4, TIM-3, and STAT3, suggesting its potential for synergistic antitumoral effects in glioma immunotherapy​​ [95, 96]. The gene discussed is CTLA4; the disease is central nervous system cancer.